Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?

It has been about a month since the last earnings report for Exact Sciences (EXAS). Shares have added about 45.4% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.

EXAS Q3 Earnings and Revenues Beat Estimates, ’25 Sales View Up

Exact Sciences Corporation (EXAS) reported earnings per share (EPS) of 24 cents in the third quarter of 2025, beating the Zacks Consensus Estimate by 84.6%. The reported figure compares to a loss of 21 cents per share a year ago. 

EXAS’ Q3 Revenues

Consolidated revenues totaled $850.7 million, up 20% on a reported as well as a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 5%.

Exact Sciences’ 2025 Outlook

For full-year 2025, the company has raised its guidance for total revenues to $3.22-$3.24 billion (earlier $3.13-$3.17 billion). The Zacks Consensus Estimate is pegged at $3.23 billion.

Among these, Screening revenues are now expected to be in the range of $2.51-$2.52 billion (earlier $2.44-$2.47 billion). Precision Oncology revenues are now anticipated to be in the band of $710-$715 million (earlier $690-$700 million). 

The adjusted EBITDA forecast has been updated to $470-$480 million (earlier $455-$475 million).

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -101.14% due to these changes.

VGM Scores

Currently, Exact Sciences has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Exact Sciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Repligen (RGEN), has gained 12.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.

Repligen reported revenues of $188.8 million in the last reported quarter, representing a year-over-year change of +21.9%. EPS of $0.46 for the same period compares with $0.43 a year ago.

Repligen is expected to post earnings of $0.44 per share for the current quarter, representing no change from the year-ago quarter. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Repligen. Also, the stock has a VGM Score of D.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research